Lumos Diagnostics Holdings Ltd (ASX: LDX) Share Price and News

Ms Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy. Formerly an Investment Director with healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was involved in over $30M of portfolio investments. In 2017, she founded ANDHealth, Australia's dedicated digital health accelerator and commercialization support organization which has led to growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles in Australia and internationally, and is a Director of ANDHealth Pty Ltd. She is Chair of the Disclosure Committee and member of Risk Committee.

Ms Robson has more than 20 years of experience in management, finance and investment. Ms. Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms. Robson's other Board appointments include serving as a Non-Executive Director for Australia's customer owned bank, Newcastle Greater Mutual Group, where she chairs the Audit Committee. She is Chair of the Risk Committee.

Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its Accelerate Pheno instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice.

Mr Lanyon has more than 25 years of experience in strategy, sales and operations with a track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and Vision Systems Ltd where he was responsible for establishing Vision Biosystem's sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific. He is member of the Disclosure Committee and Risk Committee.

Mr Ward has more than 30 years of biotech and medical technology experience at global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results. Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.

-

-

-

-

-

-

-

-

-

-